Innoviz Technologies reports Q1 results tomorrow with a striking divergence between its lending market and its options positioning — a split that frames the debate heading into the print.
The borrow market signals deeply entrenched short conviction. Short interest runs at nearly 10% of the free float, and availability has effectively collapsed — the lending pool has been fully utilised for most of the past six weeks, meaning there are almost no shares left to borrow. The ORTEX short score of 76.5 ranks in the first percentile of the universe on both days-to-cover and utilisation measures. Cost to borrow has crept up roughly 19% over the past week to just over 3%, a modest but directionally meaningful move in a market where borrow is already maxed out. Short sellers have not flinched despite a sharp rally: the stock jumped 9.6% on Monday and is up nearly 19% over the past week, yet short interest has barely shifted — declining less than half a percentage point over that period.
Options traders are reading the tape differently. The put/call ratio has dropped to 0.067, the lowest reading of the past year and more than two standard deviations below its 20-day average of 0.09. That is an unusually call-heavy posture — the ratio has gone from one of its higher recent levels in mid-April toward its most bullish extreme just as the stock has surged. The contrast with the short book is stark: while shorts refuse to cover, options flow is tilting aggressively toward upside participation.
Goldman Sachs adds another layer to the debate. The bank's analyst downgraded INVZ to Neutral from Buy in mid-April, slashing the price target from $1.25 to $0.75 — below where the stock traded as recently as last week. That move undercuts the bull case, which centres on anticipated vehicle production starting in 2027 and an estimated revenue run-rate of around $100 million by FY26. Bears point to the risk of production delays in LiDAR series manufacturing, a challenging macro backdrop, and SPAC-vintage balance sheet pressures. One smaller firm, Amerx, initiated coverage with a Buy and a $2.77 target on Monday — a bullish counterpoint, though its weight in the consensus is limited. The two-analyst panel sits at a Hold, with targets straddling the current price of $0.80 by a wide margin.
Past prints have not rewarded buyers. The two most recent earnings events each resulted in the stock falling roughly 4-5% over the following five days. Peers in the LiDAR and sensing space have had a mixed week — NEON fell nearly 8% on Monday, OUST dropped around 5% over the week, and ARBE also slipped — making Innoviz's 19% weekly gain stand out as idiosyncratic rather than sector-driven.
Tomorrow's print is less a test of whether LiDAR demand is growing and more a test of whether Innoviz can show enough commercial momentum to justify the stock's sudden re-rating — and to resolve the standoff between a short book that refuses to move and an options market signalling something very different.
See the live data behind this article on ORTEX.
Open INVZ on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
